Improved adenoviral vectors for gene therapy of Duchenne muscular dystrophy

Neuromuscular Disorders

Volumn 7, Issue 5, 1997, Pages 277-283

  Hauser, M A ^a   Amalfitano, A ^a   Kumar Singh, R ^a   Hauschka, S D ^b   Chamberlain, J S ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Adenovirus; Creatine kinase; Duchenne muscular dystrophy; Dystrophin; Encapsidated mini chromosome; Gene therapy; mdx mice

Indexed keywords

DYSTROPHIN; VIRUS VECTOR;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DUCHENNE MUSCULAR DYSTROPHY; FEASIBILITY STUDY; GENE TARGETING; GENE THERAPY; MOUSE; MUSCLE; NONHUMAN; PRIORITY JOURNAL; TISSUE SPECIFICITY; TRANSGENIC MOUSE; VIRAL GENETICS;

ADENOVIRIDAE; ANIMALS; CAPSID; CHROMOSOMES; CREATINE KINASE; DEFECTIVE VIRUSES; DYSTROPHIN; GENE THERAPY; GENETIC VECTORS; MICE; MICE, INBRED MDX; MICE, TRANSGENIC; MUSCLES; MUSCULAR DYSTROPHY, ANIMAL; MUTAGENESIS, INSERTIONAL; VIRUS REPLICATION;

EID: 0030763563     PISSN: 09608966     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-8966(97)00052-7     Document Type: Article

References (26)

1. Sicinski P, Geng Y, Ryder-Cook AS, Barnard EA, Darlison MG, Barnard PJ. The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science 1989;244:1578-1580.
2. Cox GA, Phelps SF, Chapman VM, Chamberlain JS. New mdx mutation disrupts expression of muscle and non-muscle isoforms of dystrophin. Nat Genet 1993;4:87-93.
3. Im WB, Phelps SF, Copen EH, Adams EG, Slightom JL, Chamberlain JS. Differential expression of dystrophin isoforms in multiple strains of mdx mice. Hum Mol Genet 1996;5:1149-1153.
4. Lee CC, Pearlman JA, Chamberlain JS, Caskey CT. Expression of recombinant dystrophin and its localization to the cell membrane. Nature 1991;349:334-336.
5. Bies RD, Phelps SF, Cortez MD, Roberts R, Caskey CT, Chamberlain JS. Human and murine dystrophin mRNA transcripts are differentially expressed during skeletal muscle, heart and brain development. Nucleic Acids Res 1992;20:1725-1731.
6. Graham FL, Prevec L. Manipulation of adenovirus vectors. In: Methods in Molecular Biology, Vol. 7: Gene Transfer and Expression Protocols. Murray EJ, ed. Clifton, NJ: The Human Press, 1991:109-128.
7. Kumar-Singh R, Chamberlain JS. Encapsidated adenovirus mini-chromosomes allow delivery and expression of a 14 kb dystrophin cDNA to muscle cells. Hum Mol Genet 1996;5:913-921.
8. Hogan B, Constantini F, Lacey E. Manipulating the Mouse Embryo: A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1986.
9. Phelps SF, Hauser MA, Cole NM, et al. Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice. Hum Mol Genet 1995;4:1251-1258.
10. McCully KK, Faulkner JA. Length-tension relationship of mammalian diaphragm muscles. J Appl Physiol 1984;54:1681-1686.
11. Brooks SV, Faulkner JA. Forces and powers of slow and fast skeletal muscles in mice during repeated contractions. J Physiol 1991;436: 701-710.
12. Jaynes JB, Chamberlain JS, Buskin JN, Johnson JE, Hauschka SD. Transcriptional regulation of the muscle creatine kinase gene and regulated expression in transfected mouse myoblasts. Mol Cell Biol 1986;6:2855-2864.
13. Johnson JE, Wold BJ, Hauschka SD. Muscle creatine kinase sequence elements regulating skeletal and cardiac muscle expression in transgenic mice. Mol Cell Biol 1989;9:3393-3399.
14. Chamberlain JS, Jaynes JB, Hauschka SD. Regulation of creatine kinase induction in differentiating mouse myoblasts. Mol Cell Biol 1985;5:484-492.
15. Cox GA, Cole NM, Matsumura K, et al. Overexpression of dystrophin in transgenic mdx mice eliminates dystrophic symptoms without toxicity. Nature 1993;364:725-729.
16. Rafael JA, Sunada Y, Cole NM, Campbell KP, Faulkner JA, Chamberlain JS. Prevention of dystrophic pathology in mdx mice by a truncated dystrophin isoform. Hum Mol Genet 1994;3:1725-1733.
17. Rafael JA, Cox GA, Corrado K, Jung D, Campbell KP, Chamberlain JS. Forced expression of dystrophin deletion constructs reveals structure-function correlations. J Cell Biol 1996;134:93-102.
18. Jaynes JB, Johnson JE, Buskin JN, Gartside CL, Hauschka SD. The muscle creatine kinase gene is regulated by multiple upstream elements, including a muscle-specific enhancer. Mol Cell Biol 1988;8:62-70.
19. Amacher SL, Buskin JN, Hauschka SD. Multiple regulatory elements contribute differentially to muscle creatine kinase enhancer activity in skeletal and cardiac muscle. Mol Cell Biol 1993;13:2753-2764.
20. Buckingham ME. Muscle protein synthesis and its control during the differentiation of skeletal muscle cells in vitro. Int Rev Biochem 1977;15:269-332.
21. Donoviel DB, Shield MA, Buskin JN, Haugen HS, Clegg CH, Hauschka SD. Analysis of muscle creatine kinase gene regulatory elements in skeletal and cardiac muscles of transgenic mice. Mol Cell Biol 1996;16:1649-1658.
22. Yang Y, Nunes FA, Berencsi K, Furth EE, Gonczol E, Wilson JM. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994;91:4407-4411.
23. Yang Y, Li Q, Ertl HCJ, Wilson JM. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol 1995;69:2004-2015.
24. Thomas GP, Mathews MB. DNA replication and the early to late transition in adenovirus infection. Cell 1980;22:523-533.
25. Amalfitano A, Begy CR, Chamberlain JS. Improved adenovirus packaging cell lines to support the growth of replication-defective gene-delivery vectors. Proc Natl Acad Sci USA 1996;93:3352-3356.
26. Amalfitano A, Chamberlain JS. Isolation and characterization of packaging cell lines that coexpress the adenovirus E1, DNA polymerase, and preterminal proteins: implications for gene therapy. Gene Ther 1997;4:258-263.